Phase I study of AR-42 and decitabine in acute myeloid leukemia

This phase I trial sought to determine a biologically safe and effective dose of AR-42, a novel histone deacetylase inhibitor, which would lead to a doubling of miR-29b prior to decitabine administration. Thirteen patients with previously untreated or relapsed/refractory AML were treated at 3 dose l...

詳細記述

保存先:
書誌詳細
出版年:Leuk Lymphoma
主要な著者: Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Blum, William, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Geyer, Susan, Zhao, Qiuhong, Garzon, Ramiro, Marcucci, Guido, Phelps, Mitch A., Walker, Alison R.
フォーマット: Artigo
言語:Inglês
出版事項: 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375689/
https://ncbi.nlm.nih.gov/pubmed/32037935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1719095
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料